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Abstract
Background Data on long-term outcomes in children who have received renal replacement therapy (RRT) for end-stage renal
disease are limited.
Methods We studied long-term survival and incidence of fatal and nonfatal cardiovascular disease (CVD) events and determi-
nants of these outcomes in children who initiated RRT between 1961 and 2013 using data from the Scottish Renal Registry
(SRR). Linkage to morbidity records was available from 1981.
Results A total of 477 children of whom 55% were boys, almost 50% had congenital urinary tract disease (CAKUT), 10%
received a transplant as the first mode of RRT and almost 60% were over 11 years of age at start of RRT were followed for a
median of 17.8 years (interquartile range (IQR) 8.7–26.6 years). Survival was 87.3% (95% confidence interval (CI) 84.0–90.1) at
10 years and 77.6% (95%CI 73.3–81.7) at 20 years. During a median follow-up of 14.96 years (IQR 7.1–22.9), 20.9% of the 381
patients withmorbidity data available had an incident of CVD event. Age < 2 years at start of RRT, receiving dialysis rather than a
kidney transplant and primary renal disease (PRD) other than CAKUTor glomerulonephritis (GN), were associated with a higher
risk of all-cause mortality. Male sex, receiving dialysis rather than a kidney transplant and PRD other than CAKUT or GN, was
associated with a higher risk of CVD incidence.
Conclusions Mortality and CVD incidence among children receiving RRTare high. PRD and RRTmodality were associatedwith
increased risk of both all-cause mortality and CVD incidence.
Keywords End-stage renal disease . Dialysis . Dransplant . Children .Mortality . Cardiovascular disease
Introduction
End-stage renal disease (ESRD) in children is rare with median
global incidence of renal replacement therapy (RRT) estimated
to be nine children per million aged 4–18 years in 2008 [1].
Nevertheless, it is a serious healthcare problem requiring RRT
in the form of dialysis or kidney transplantation to sustain life
[2]. Recent data from the European Renal Registry
(ESPN/ERA-EDTA) show that the incidence of RRT among
children aged 0–14 years is around six permillion each year [3].
Mortality rates in children receiving RRT are much higher than
in the age and sex-matched general population [4].
Cardiovascular disease (CVD) is the leading cause of death in
these children, responsible for 23–60% of all deaths [4–7].
Several factors are known to be associated with mortality risk.
These include modality at start of RRT, with children who
started RRTwith dialysis having an almost seven times higher
risk of mortality compared to those who received a pre-emptive
kidney transplant (HR 6.6, 95% CI 2.9–14.8) [8]. Younger age
at start of RRT [4–11], female sex [5] and primary renal disease
(PRD) other than congenital anomalies of kidney and urinary
tract (CAKUT) [4, 5, 12] have also been found to be associated
with increased risk of mortality among children receiving RRT.
Studies so far have generally reported 5-year survival [6, 8, 13].
Only limited data exist about longer-term survival [4, 14, 15]
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and incidence of nonfatal CVD events [9, 11] in individuals
who start RRT in childhood. The aims of this study were to
describe long-term survival and incidence of fatal and nonfatal
CVD events in children after starting RRT and to describe the
association between age at initiation of RRT, sex, PRD and
RRT modality and these outcomes.
Materials and methods
Study population
We included all children (aged <18 years) from the Scottish
Renal Registry (SRR) who started RRT between January 1,
1961 and December 31, 2013. The SRR is a national registry
that collects individual patient data on date of birth, sex, PRD,
start date of RRT, treatment modality at start of RRT, any
subsequent changes in treatment modality and vital status for
all people starting RRT in Scotland [16].
Data linkage
To describe mortality and CVD incidence, we linked data
from National Records of Scotland (NRS) death records and
the Scottish Morbidity Records (SMR01) database from
Information Services Division (ISD) Scotland with SRR data.
The SMR01 database holds data on inpatient and day-case
hospital discharges in Scotland from 1981 onwards [17].
Therefore, we selected a sub-cohort of the SRR patients who
started RRT from 1981 and 2013 to describe the incidence of
fatal and nonfatal CVD events (Fig. 1). We obtained approval
for the data linkage and analysis from the Public Benefit and
Privacy Panel for Health and Social Care (PBPP) [18] and the
SRR steering group. We stored and accessed all datasets ac-
cording to ISD information governance rules and processes.
Follow-up period
We followed patients from the start of RRT until the outcome
of interest, the end of observation period (December 31, 2015)
or loss to follow-up, whichever came first.
Outcome variables
All-cause mortality and CVD incidence were the outcomes of
interest. We defined CVD incidence using the first CVD event
after the start of RRT in any position listed in the SMR01
database or in NRS death records. We defined fatal CVD
events from the NRS death records from International
Classification of Disease (ICD) codes for any circulatory dis-
ease. We categorised fatal CVD events as ischaemic heart
disease, cerebrovascular disease, heart failure, cardiac arrest/
arrhythmias, cardiomyopathy and other diseases of the circu-
latory system. We did not include codes for other diseases of
the circulatory system in the definition of nonfatal CVD
events (Table 1).
We categorised patients in accordance with previous pub-
lications into the following four age groups at start of RRT: 0–
<2 years old, 2–<6 years old, 6–<12 years old and 12–<18
years old [19, 20]. We classified PRD according to the ERA-
EDTA coding system [21] and grouped it as CAKUT, glomer-
ulonephritis (GN) and other. The other category includes cys-
tic kidney disease, hereditary nephropathy, ischaemic renal
failure, haemolytic-uraemic syndrome (HUS), metabolic
Fig 1 Flow chart describing the
study population of children who
started renal replacement therapy
in Scotland
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disorders, vasculitis and miscellaneous. We categorised initial
type of RRT as haemodialysis (HD), peritoneal dialysis (PD)
and pre-emptively transplanted (pre-Tx). We classified RRT
patterns during follow-up into four categories: started on HD
and not transplanted during follow-up (HD + Tx-), started on
PD and not transplanted during follow-up (PD + Tx-), pre-Tx
and transplanted ever after starting RRTon dialysis (D + Tx+).
Statistical methods
We calculated crude all-cause mortality and CVD incidence
rates per 100 person years of follow-up. We used unadjusted
cumulative incidence competing risk (CICR) analysis to esti-
mate the risk of mortality and cardiovascular disease by initial
RRT modality [22] and accompanying 95% confidence inter-
vals [23]. Cause-specific Cox proportional hazard regression
analyses were used to describe survival probabilities and risk
of outcomes by age at start of RRT, sex, PRD and RRT mo-
dality. Patients were censored after experiencing the outcome
of interest as only first occurring events are taken into account.
We evaluated the proportional hazard assumption graphically
using log minus log plots. We adjusted the estimates of asso-
ciations from Cox proportional hazard models for possible
confounding factors including age at start of RRT, sex, PRD,
initial RRT modality and period of start of RRT (1961–1990,
1991–2000 and 2001–2013). Data were complete for all var-
iables included in the Cox regression analyses.
Sensitivity analysis
Since children who receive pre-emptive transplants (i.e. those
who do not receive dialysis prior to transplant) generally have
better survival than children who initially receive dialysis, we
performed a sensitivity analysis excluding children who re-
ceived a pre-emptive transplant from the Cox regression anal-
ysis. We compared the results of this sensitivity analysis with
the results of the main analyses.
Results
Patient characteristics
Table 2 presents the demographic characteristics of the 477
children included in the all-cause mortality analyses and the
381 children included in the analyses of CVD incidence. The
characteristics of both cohorts show that the proportion of
boys was higher than girls and the majority of the patients
started RRT when they were older than 12 years of age.
Furthermore, CAKUT was the most common underlying
PRD, and almost 90% of patients started RRT on dialysis,
and only 10% of children received a pre-emptive transplant.
Survival after the start of renal replacement therapy
In total, 477 children were followed for a median of 17.8 years
(IQR 8.7–26.6 years), giving a total follow-up time of 8710
person years. Median follow-up time was longest for patients
starting RRTon HD (21.5 year), followed by PD (17.2 years),
and pre-emptive transplant patients had the shortest median
follow-up time of 14.2 years. During the total study period,
125 patients died resulting in a crude all-cause mortality rate
of 1.44 (95% CI 1.19–1.70) per 100 person years. Of these
deaths, 36.5% were due to a known cardiovascular cause,
11.2% of the deaths were due to infections, 5.6% due to ma-
lignancies, and 2.4% caused by haemorrhages. After 10 years
of follow-up, the overall survival after the start of RRT was
87.3% (95% CI 84.0–90.1), and 337 were still alive with
follow-up available, after 20 years overall survival was
77.6% (95% CI 73.3–81.7), and 209 children were still
followed-up. Mortality was lower in children who received a
pre-emptive transplant compared to children who received
HD as their first RRT (0.55, 95% CI 0.01–1.09 per 100 person
years and 1.68, 95% CI 1.31–2.06 per 100 person years, re-
spectively) or children who started with PD (1.29, 95% CI
0.91–1.67 per 100 person years) although a statistically
Table 1 ICD-9 and ICD-10 codes used for fatal and nonfatal CVD events
CVD events Nonfatal CVD events Fatal CVD events
ICD-9 ICD-10 ICD-9 ICD-10
Ischaemic heart disease 410–414 I20–I25 410–414 I20–I25
Cerebrovascular disease 430–438 I60–I69 430–438 I60–I69
Heart failure 428 I50 428 I50
Cardiac arrest/arrhythmias 427 I46–I49 427 I46–I49
Cardiomyopathy 425 I42, I43 425 I42, I43
Other diseases of circulatory system - - 390-405, 415-417, 420-424,
426, 429, 440-459
I00–I15, I26–I28, I30–I41, I44,
I45, I51, I52, I70–I99
CVD; cardiovascular disease, ICD; international classification of diseases -9 indicates ninth revision used to classify death records and hospital records
until 1999, -10 indicates tenth revision used after 1999 to classify death records and hospital records
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significant difference was only observed for the comparison
between children receiving a pre-emptive transplant and those
receiving HD as their first RRT. Figure 2 presents cumulative
incidence curves based on unadjusted CICR analyses. This
figure shows that after 10 and 20 years, follow-up survival
among patients who started on HD was 87.1% (95% CI
82.2–91.3) and 75.0% (95% CI 68.6–81.0); on PD these fig-
ures were 86.1% (95% CI 80.9–90.5) and 78.3% (95% CI
71.6–84.4). Patients who received a pre-emptive transplant
showed higher survival (after 10 years 92.5% (95% CI
81.4–98.1) and 20 years 89.4% (95% CI 76.9–96.8)).
Cardiovascular disease incidence after the start
of renal replacement therapy
The cohort included in the CVD incidence analyses of 381
children was followed for a median of 14.96 (IQR 7.05–
22.87) years with a total follow-up of 5739 person years.
The mean age at the first CVD event was 22.1 (standard de-
viation ± 9.4) years. In total 80 (20.9%) children experienced a
CVD event of which 20 had a fatal event. The most common
types of CVDwere cerebrovascular disease (N = 29) followed
by heart failure (N = 13), cardiac arrest/arrhythmias (N = 13)
and other (N = 12 of which 55% were due to cardiomegaly
and 27% were classified as endocarditis), ischaemic heart dis-
ease (N = 11) and cardiomyopathy (N = 2).
The overall CVD incidence was 1.39 (95% CI 1.09–1.70)
per 100 person years. CVD incidence was lowest among pre-
Tx children (0.93, 95% CI 0.19–1.67 per 100 person years)
compared with children who started with HD (1.87, 95% CI
1.33–2.43) per 100 person years) or PD (1.08, 95% CI 0.68–
1.47 per 100 person years) (Fig. 3), but these differences were
not statistically significant. Figure 3 shows the cumulative
incidence curves based on unadjusted CICR analyses.
Associations between determinants and all-cause
mortality and cardiovascular disease incidence
Table 3 presents the results of the cause-specific Cox propor-
tional hazard analyses showing associations between age at
start of RRT, sex, PRD and RRT modality with all-cause





Characteristics N (%) N (%)
N included 477 381
Sex
Male 264 (55.3) 218 (57.2)
Age at start of RRT (years)
0–<2 30 (6.3) 29 (7.6)
2–<6 50 (10.5) 47 (12.3)
6–<12 113 (23.7) 90 (23.6)
12–<18 284 (59.5) 215 (56.4)
PRD
CAKUT 229 (48.0) 180 (48.6)
GN 80 (16.8) 59 (15.5)
Other 168 (35.2) 137 (36.0)
Initial RRT modality
HD 220 (46.1) 155 (40.7)
PD 207 (43.4) 180 (47.2)
Tx 50 (10.5) 46 (12.1)
RRT modality during follow-up
D + Tx+ 371 (77.8) 289 (75.9)
Pre-Tx 50 (10.5) 46 (12.1)
HD + Tx- 30 (6.3) 24 (6.3)
PD + Tx- 26 (5.5) 22 (5.8)
CVD cardiovascular disease, RRT renal replacement therapy, PRD prima-
ry renal disease, CAKUT congenital anomalies of kidney and urinary
tract, GN glomerulonephritis, HD haemodialysis, PD peritoneal dialysis,
Tx transplanted. PD + Tx started on PD and not transplanted during
follow-up, HD + Tx started on HD and not transplanted during follow-
up, pre-Tx pre-emptive transplant, D + Tx + started on dialysis (PD or
HD) and received a transplant during follow-up
Fig 2 Cumulative incidence
curves for mortality in Scottish
children after start of renal
replacement therapy between
1961 and 2013 by initial renal
replacement therapy modality
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mortality and CVD incidence. Starting RRT at a very young
age (0–2 years), PRD other than CAKUTor GN and receiving
dialysis rather than a kidney transplantation as the initial RRT
modality are significantly associated with increased risk of all-
cause mortality. Furthermore, these results show that patients
who never received a transplant have an increased mortality
risk compared with patients who are pre-emptively
transplanted or who received a transplant during follow-up.
Sex was not associated with all-cause mortality, but boys/men
had an increased risk of CVD compared to girls/women. Other
factors associated with increased risk of CVDwere PRD other
than CAKUT or GN and receiving no transplant during fol-
low-up. Similar results were obtained in a sensitivity analysis
excluding 50 children who received a pre-emptive transplant .
Discussion
Summary of principal findings
In this study, we described survival and CVD incidence in
children who started RRT after 1961 in Scotland and investi-
gated how key patient and treatment factors were associated
with these outcomes. Of the 477 children who started RRT in
Scotland between 1961 and 2013, 125 died during a total of
8.710 person years of follow-up. Unadjusted cumulative sur-
vival for the cohort was 87.3% at 10 years and 77.6% at 20
years. Survival was highest in patients who received a pre-
emptive transplant and lowest in patients who started RRT on
HD and did not receive a transplant during follow-up. Other
factors associated with poorer survival were underlying PRD
other than CAKUT or GN and starting RRT at a very young
age. During a median follow-up of almost 15 years, 21% of
the patients developed incident CVD with the most common
type being cerebrovascular disease. CVD incidence was not
significantly associated with initial mode of RRT. Boys/men
had an increased risk of CVD incidence compared to girls/
women. PRD other thanCAKUTorGN and receiving dialysis
rather than a kidney transplantation were associated with in-
creased risk of CVD.
Comparison of all-cause mortality with previous
studies
Our findings were similar to the 86% cumulative 10-year sur-
vival reported from a Canadian cohort including 843 children
starting RRT between 1992 and 2007 [15]. However,
McDonald and Craig reported slightly lower survival figures
based on older data from the Australian and New Zealand
(ANZDATA) registries collected between 1963 and 2002
[4], and the ERA/EDTA has published higher overall long-
term cumulative survival figures based on recent data from
Europe [24]. The variation of these survival rates can at least
partly be explained by differences in study period included in
the analyses. For example, data from ANZDATA showed in-
creased survival [4] due to availability of effective treatments
[24].
Several other reports have studied the association between
key patient and treatment factors and all-cause mortality.
Consistent with the findings of previous studies, we found that
the youngest age group (<2 years at start of RRT) had the
highest mortality [5, 15, 24].
Unsurprisingly, we found the highest survival among chil-
dren who received a pre-emptive transplants and lowest sur-
vival among patients who never received a transplant [25].
This finding is in line with earlier studies [26]. Although this
finding supports the likely benefit of transplant, there is also
the strong possibility that failure to receive a transplant may
also be a marker of high risk of mortality due to coexistent
conditions that preclude listing for transplantation.
We found the highest all-cause mortality in children with
an underlying PRD other than CAKUT or GN which is con-
sistent with reports from a cohort including Canadian infants
[15] and reports based on USRDS data [5].
We found that boys had an increased risk of all-cause mor-
tality compared with girls; however this effect was not
Fig 3 Cumulative incidence
curves for cardiovascular disease
in Scottish children after start of
renal replacement therapy




statistically significant. In contrast a study using USRDS
data including both dialysis and transplant patients showed
a higher mortality among girls after a median follow-up of
7 years (HR 1.36 (95% CI 1.25–1.50)). Sex disparities in
access to (pre-emptive) transplantation, health insurance
and underlying PRD only partly explained the difference
in survival [27]. A few other studies have shown higher
mortality among girls [5, 28], but a short follow-up or only
including dialysis patients makes comparison with our re-
sults difficult.
Comparison of cardiovascular outcomes
with previous studies
It is well-known that similar to results from the adult RRT
population, the proportion of deaths in the paediatric RRT
population attributed to CVD is high [7, 8, 14, 27, 29].
However, there are only limited data available on CV out-
comes including CV morbidity. A few studies have reported
on fatal and nonfatal CVD, but these studies were limited to a
short follow-up, a selected population and lacking detailed
specification of the type of CVoutcomes [9, 29].
One of the few sources reporting the incidence of CVD
events is the USRDS. Data from this source showed that
first-year CVD hospitalisation are common (rates of 63 per
1000 patient years from 2005 to 2009 and 42 from 2010 to
2014). The highest risk of CVD hospitalisation occurred
among children on dialysis which is in agreement with our
results. Chavers et al. reported that around a third of the pa-
tients who started dialysis between 1990 and 1997 developed
a cardiac-related event. Of these events, the majority were
arrhythmias, valvular heart disease, cardiomyopathy and car-
diac arrests. Children in the oldest age group (15–19 years),
blacks and girls, had the highest rates of cardiac-related events
Table 3 Crude and adjusted
hazard ratios for associations
between determinants and all-
cause mortality and cardiovascu-
lar disease incidence









Age at start of RRTa
0–<2 2.41 (1.27–4.57) 2.87 (1.42–5.82) 0.73 (0.27–2.02) 0.89 (0.31–2.59)
2–<6 0.93 (0.60–1.44) 1.39 (0.67–2.67) 0.54 (0.23–1.25) 0.77 (0.32–1.91)
6–<12 0.97 (0.50–1.89) 1.04 (0.66–1.64) 0.67 (0.38–1.17) 0.79 (0.44–1.41)
12–18 1.00 1.00 1.00 1.00
Sexb
Males 1.27 (0.89–1.82) 1.31 (0.92–1.88) 1.51 (0.96–2.38) 1.76 (1.11–2.79)
Females 1.00 1.00 1.00 1.00
PRDc
GN 0.99 (0.61–1.65) 1.01 (0.61–1.69) 1.17 (0.63–2.18) 1.12 (0.59–2.19)
Other 1.45 (0.98–2.13) 1.50 (1.01–2.22) 1.46 (0.90–2.37) 1.67 (1.01–2.75)
CAKUT 1.00 1.00 1.00 1.00
Initial RRT modalityd
HD 2.97 (1.08–8.07) 2.57 (0.92–7.18) 2.04 (0.86–4.78) 1.73 (0.73–4.11)
PD 2.41 (0.87–6.70) 2.06 (0.73–5.85) 1.17 (0.49–2.82) 1.38 (0.56–3.41)
Pre-Tx 1.00 1.00 1.00 1.00
RRT modality during
follow-upe
HD + Tx- 14.4 (8.01–25.77) 20.03 (10.77–37.25) 5.51 (2.14–14.16) 6.20 (2.29–16.80)
PD + Tx- 17.3 (9.71–30.76) 20.69 (10.73–39.89) 5.50 (2.41–12.55) 5.81 (2.50–13.50)
Pre-Tx 0.55 (0.20–1.51) 0.68 (0.25–1.86) 0.74 (0.32–1.71) 0.69 (0.30–1.61)
D + Tx+ 1.00 1.00 1.00 1.00
CVD cardiovascular disease; HR hazard ratio, CI confidence interval; RRT renal replacement therapy; PRD
primary renal disease; GN glomerulonephritis, CAKUT congenital anomalies of kidney and urinary tract; HD
haemodialysis; PD peritoneal dialysis; pre-Tx pre-emptively transplanted; HD + Tx started on HD and not
transplanted during follow-up, PD + Tx started on PD and not transplanted during follow-up, D + Tx +
transplanted ever after starting on dialysis. Only patients with complete data included in unadjusted and adjusted
analyses; adjusted for a sex, PRD, type of RRTat start and period of start of RRT; b age at start of RRT, PRD, type
of RRTat start and period of start of RRT; c age at start of RRT, sex, type of RRTat start and period of start of RRT;
d age at start of RRT, sex, PRD and period of start of RRT; e age at start of RRT, sex, PRD and period of start of
RRT
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[11]. Different inclusion criteria and follow-up make it diffi-
cult to directly compare these findings with our results. A
possible explanation for the overall lower incidence of CVD
events we found (21% compared with 30% based on USRDS
data) might be the fact that our population is predominantly
Caucasian. Previous studies have reported a high prevalence
of a variety of intermediate CVoutcomes and CVabnormali-
ties such as left ventricular hypertrophy, coronary calcifica-
tions, arrhythmias and significantly increased carotid intima
media thickness in children and young adults who started RRT
in childhood [30–35]. These results are in agreement with our
findings of a high incidence of CVD after long-term follow-up
during young adult age (mean age of first CVD event of 21
years) and increased CVD risk among both dialysis and trans-
plant patients compared with general population.
Furthermore, high prevalence of traditional CV risk factors
and newer risk factors such as C-reactive protein among dial-
ysis and transplanted patients is reported [27]. For example, a
cross-sectional analysis of prevalent RRT patients in the
United Kingdom has shown that 75% of patients younger than
18 years old have one or more CV risk factor (obesity, hyper-
tension, hypercholesterolaemia), and one in ten have all three
risk factors [36]. These findings raise the expectation of high
incidence of fatal and nonfatal CVD incidence in this
population.
Strengths and limitations of the study
In our study, data from all incident paediatric RRT patients in
Scotland are included. A novel data linkage with death and
hospital admission data offered the opportunity to describe
fatal and nonfatal incident CVD events as well as all-cause
mortality during follow-up period into adulthood. The study
cohort is extremely heterogeneous because all patients who
started RRT in Scotland in a certain period are included. This
has resulted in a cohort which covers several decades and
includes both dialysis and transplant patients (pre-emptively
and transplanted during follow-up), a variety of PRDs, infants,
children and adolescents resulting in a diverse case mix. We
were therefore able to investigate the effect of these diverse
characteristics onmortality and CVD incidence and found that
the sensitivity analysis excluding children who received a pre-
emptive transplant (N = 50) found similar results to the main
analysis.
A key limitation is the relatively small sample size despite
this study being a population wide study including all incident
RRT patients in Scotland over a 50-year calendar period. The
small sample size has resulted in low statistical power and
precision and limited ability to perform potentially interesting
analyses in subgroups of the cohort. Future studies including a
larger cohort will offer opportunities to look at analyses strat-
ified by underlying PRD and the impact of time (different
types) of RRTon cardiovascular risk in children after initiating
RRT. Although important possible confounding variables are
taken into account, information on existing comorbidities is
not available.
A final potential limitation is that data on causes of death
and hospital admissions before 1981 are not available, and
therefore it might be possible that a small proportion of the
children currently classified as having new onset CVD had an
earlier CVD event prior to 1981.
Conclusion and clinical implications
In summary, our study shows that 87% and 78% of
children who started RRT in Scotland between 1961
and 2013 were still alive after 10 and 20 years of fol-
low-up. Long-term survival was highest in patients who
receive a pre-emptive transplant, who have CAKUT or
GN as PRD and who start RRT at older age. After a
median follow-up of 13 years, a fifth of the children
developed incident CVD. Male sex, dialysis as treat-
ment modality and PRD other than CAKUT or GN
were associated with higher risk of CVD. It is important
that physicians providing care to young adults who
started RRT during childhood are aware of the implica-
tions of childhood illness upon cardiovascular risk.
Furthermore, our results showed that patients who re-
ceived a pre-emptive transplant had a lower risk of
all-cause mortality and CVD outcomes. Recent data
from the UK Renal Registry showed that less than a
quarter of paediatric RRT patients received a pre-
emptive transplant [33]. To prevent early mortality and
CVD pre-emptive transplantation should be promoted.
Our results strongly suggest that the effectiveness of
monitoring and treating CV risk factors children on RRT
and young adults who started RRT during childhood
should be assessed. The results of the Dutch LERIC co-
hort have shown promising results of intensified antihyper-
tensive and antidyslipidaemic therapy in young adults who
started RRT in childhood. In this cohort of 249 patients
who started RRT in childhood and survived into adulthood
(follow-up of 25.5 years), a clear decrease in CV mortality
along with strict CV management and reversal of CV risk
factors was observed [30, 31]. A review published in 2017
describes the under-recognised and under-treated burden of
hypertension in transplant patients [37]. In addition another
study has reported on contradicting guidelines and differ-
ences in policies and treatment of hypertension in Dutch
paediatric transplant patients [38]. This evidence together
with our reported increased and ongoing CVD risk in
paediatric patients underlines the importance of further re-
search to provide evidence to develop specific guidelines
for optimal treatment of paediatric RRT patients.
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